Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Avastin [bevacizumab] Therapy in Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin.

Trial Profile

Pilot Trial of Intraperitoneal Paclitaxel and Carboplatin with IV Avastin [bevacizumab] Therapy in Treatment of Women with Newly Diagnosed, Optimally Cytoreduced Carcinoma of Mullerian Origin.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 20 Aug 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 as per ClinicalTrials.gov record.
    • 20 Aug 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Feb 2015 to 1 Feb 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top